Thiogenesis Therapeutics Corp
OTC Pink - Current Information:TTIPFView on Canadian Exchange

  • LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 0.0000
  • Day Range
    ---
  • 52 Week Range
    ---
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 17, 2024

      Show headlines and story abstract

    • 9:32AM ET on Tuesday Sep 17, 2024 by Newsfile
      Companies Mentioned: TTIPF

      San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., Ph.D., the Company's Chief Executive Officer, has been invited to present this week at the Cure Mito Foundation's "Empower and Inspire: 3rd Annual Leigh Syndrome Symposium." The Cure Mito Foundation is a global non-profit patient advocacy organization led by parents who volunteer their time to change the future for families affected by Leigh syndrome.

    • 9:32AM ET on Tuesday Sep 17, 2024 by Dow Jones
      Companies Mentioned: TTI

      San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., Ph.D., the Company's Chief Executive Officer, has been invited to present this week at the Cure Mito Foundation's "Empower and Inspire: 3(rd) Annual Leigh Syndrome Symposium." The Cure Mito Foundation is a global non-profit patient advocacy organization led by parents who volunteer their time to change the future for families affected by Leigh syndrome.

  • Aug 20, 2024

      Show headlines and story abstract

    • 11:02AM ET on Tuesday Aug 20, 2024 by MT Newswires
      Companies Mentioned: TTI
      11:02 AM EDT, 08/20/2024 (MT Newswires) -- Thiogenesis Therapeutics (TTI.V) on Tuesday said it is collaborating with the University of California San Diego (UCSD) in a proposed Phase 2 clinical trial. The trial will evaluate the company's lead candi...

    • 9:03AM ET on Tuesday Aug 20, 2024 by Dow Jones
      Companies Mentioned: TTI

      San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collaborative Agreement with the University of California San Diego ("UCSD"). Thiogenesis will work with Jeffrey Schwimmer, M.D., as the Principal Investigator at UCSD, in a proposed Phase 2 clinical trial titled: "An Open Label, Controlled Clinical Trial to Evaluate the Efficacy and Safety of TTI-0102 in Pediatric Nonalcoholic Steatosis ("NASH")."

    • 9:02AM ET on Tuesday Aug 20, 2024 by Newsfile
      Companies Mentioned: TTIPF

      San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collaborative Agreement with the University of California San Diego ("UCSD"). Thiogenesis will work with Jeffrey Schwimmer, M.D., as the Principal Investigator at UCSD, in a proposed Phase 2 clinical trial titled: "An Open Label, Controlled Clinical Trial to Evaluate the Efficacy and Safety of TTI-0102 in Pediatric Nonalcoholic Steatosis ("NASH")."

Peers Headlines

No documents available